Medinews
11 Aprile 2019

Olaparib Approved in Europe for BRCA+ Breast Cancer

April 10, 2019 – The European Commission has approved olaparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer. The decision is based on findings from the phase III OlympiAD trial, in which the PARP inhibitor reduced the risk of disease progression or death by 42% compared with chemotherapy in patients with germline BRCA-mutant, metastatic disease. With the indication, patients … (leggi tutto)

TORNA INDIETRO